You are here

obesity

Eli Lilly Has More Than an Ozempic Competitor -- Much More

Motley Fool

Wed, 02/21/24 - 11:14 am

Alzheimer's disease

Should ACA plans cover weight loss drugs?

Stat

Tue, 02/20/24 - 05:44 pm

Eli Lilly partner BioAge raises $170 mln for obesity treatment

Reuters

Tue, 02/13/24 - 11:24 am

Obesity drug mania takes over Amgen’s earnings call

BioPharma Dive

Wed, 02/7/24 - 09:17 pm

Could Novo, Lilly become first trillion-dollar healthcare companies?

Pharma Voice

Mon, 02/5/24 - 10:30 am

Regeneron Looks to Target Weight Loss Market with Muscle-Preserving Antibodies

BioSpace

Mon, 02/5/24 - 10:20 am

drug development

Fractyl Breaks the Medical Device IPO Drought with New Offering

Medical Devices and Diagnostics Industry

Sun, 02/4/24 - 12:37 pm

FDA approves NeuroBo’s DA-1726 application to begin Phase I trial

Clinical Trials Arena

Fri, 02/2/24 - 11:55 am

NeuroBo Pharmaceuticals

clinical trials

Novo Nordisk R&D spend jumps 35% thanks to soaring sales as oral obesity plans advance

Fierce Biotech

Wed, 01/31/24 - 11:55 am

Will Novo Nordisk Be a $1 Trillion Company by 2030?

Motley Fool

Tue, 01/30/24 - 10:40 am

Fractyl sets out $99M IPO ambitions after busy week of biotechs going public

Fierce Biotech

Mon, 01/29/24 - 11:13 am

Lilly's weight-loss drug Mounjaro coming to UK after pen cleared

Reuters

Thu, 01/25/24 - 09:00 pm

Many patients keep weight off after stopping anti-obesity meds: study

Axios

Wed, 01/24/24 - 10:44 am

Scholar Rock gets FDA nod to trial SMA drug with GLP-1ra in obesity

Clinical Trials Arena

Wed, 01/24/24 - 10:38 am

clinical trials

Novo Nordisk Inks Potential $255M Deal with EraCal, Targets Another Obesity Asset

BioSpace

Tue, 01/23/24 - 06:02 pm

EraCal Therapeutics

United States of Ozempic: Where anti-obesity drugs are taking off

Axios

Fri, 01/19/24 - 09:31 am

JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage

Medical Marketing and Media

Thu, 01/11/24 - 11:18 am

Amgen has potential to compete with established leaders in obesity drugs

Biopharma Reporter

Thu, 01/11/24 - 11:13 am

JPM24: In booming obesity field, Novo Nordisk is 'just getting going,' CEO says

Fierce Pharma

Wed, 01/10/24 - 06:27 pm

Lars Fruergaard Jorgensen

Zepbound shortage could be around the corner

Beckers Hospital Review

Tue, 01/9/24 - 10:05 pm

Pages